What's new in RET-positive lung cancer: Moving beyond tyrosine kinase inhibitors

This recorded Facebook Live presentation features guest speakers Nicolas Le-Bel (caregiver and member of the RETpositive patient group) and Dr. Alex Drilon (Thoracic Oncologist & Early Drug Development Specialist at Memorial Sloan Kettering Cancer Center). Dr. Drilon is also a recipient of a 2022 Hamoui Foundation/LUNGevity Lung Cancer Research Award for RET-positive lung cancer. Thank you to the Hamoui Foundation for their partnership.